These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 15173127)

  • 21. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.
    Karalliedde J; Viberti G
    J Hum Hypertens; 2006 Apr; 20(4):239-53. PubMed ID: 16452996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete inhibition of the renin-angiotensin-aldosterone system; where do we stand?
    Chen SS; Seliger SL; Fried LF
    Curr Opin Nephrol Hypertens; 2014 Sep; 23(5):449-55. PubMed ID: 25014549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.
    Weir MR
    J Hum Hypertens; 2007 Oct; 21(10):770-9. PubMed ID: 17597800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K; Miller NH
    J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of angiotensin receptor blockers in diabetic nephropathy.
    Sharma AM; Weir MR
    Postgrad Med; 2011 May; 123(3):109-21. PubMed ID: 21566421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does interference with the renin-angiotensin system protect against diabetes? Evidence and mechanisms.
    van der Zijl NJ; Moors CC; Goossens GH; Blaak EE; Diamant M
    Diabetes Obes Metab; 2012 Jul; 14(7):586-95. PubMed ID: 22226145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?
    Karagiannis A; Mikhailidis DP; Athyros VG; Kakafika AI; Tziomalos K; Liberopoulos EN; Florentin M; Elisaf M
    Expert Opin Ther Targets; 2007 Feb; 11(2):191-205. PubMed ID: 17227234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sympathetic and renin-angiotensin systems contribute to increased blood pressure in sucrose-fed rats.
    Freitas RR; Lopes KL; Carillo BA; Bergamaschi CT; Carmona AK; Casarini DE; Furukawa L; Heimann JC; Campos RR; Dolnikoff MS
    Am J Hypertens; 2007 Jun; 20(6):692-8. PubMed ID: 17531930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease.
    Mancia G; Dell'Oro R; Quarti-Trevano F; Scopelliti F; Grassi G
    J Hypertens Suppl; 2006 Mar; 24(1):S51-6. PubMed ID: 16601574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obesity, essential hypertension and renin-angiotensin system.
    Segura J; Ruilope LM
    Public Health Nutr; 2007 Oct; 10(10A):1151-5. PubMed ID: 17903324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A; Salazar J
    Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renin inhibition--benefit beyond hypertension control.
    Kher V
    J Assoc Physicians India; 2009 Jul; 57():518-20, 525. PubMed ID: 20329413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in essential hypertension].
    Burnier M
    Drugs; 2002; 62 Spec No 1():21-9. PubMed ID: 12036386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin-resistant lipolysis in abdominally obese hypertensive individuals. Role of the renin-angiotensin system.
    Hennes MM; O'Shaughnessy IM; Kelly TM; LaBelle P; Egan BM; Kissebah AH
    Hypertension; 1996 Jul; 28(1):120-6. PubMed ID: 8675251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Obesity hypertension. Converting enzyme inhibitors and calcium antagonists.
    Frohlich ED
    Hypertension; 1992 Jan; 19(1 Suppl):I119-23. PubMed ID: 1730448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antihypertensive therapy in the obese hypertensive patient.
    Chrostowska M; Szczech R; Narkiewicz K
    Curr Opin Nephrol Hypertens; 2006 Sep; 15(5):487-92. PubMed ID: 16914960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obesity hypertension: the rationale for renin-angiotensin system blockade.
    Chan NN; Tong PC; Kong AP; Chan JC
    Hong Kong Med J; 2005 Jun; 11(3):217-20. PubMed ID: 15951590
    [No Abstract]   [Full Text] [Related]  

  • 40. Metabolic syndrome: treatment of hypertensive patients.
    Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
    Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.